Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

BIOLOGICAL(8)
DRUG(2)
30 μg dose of SYS6006
2 trials
phase_1
cspc-zhongqi-pharmaceutical-technology-co-ltd
20 μg dose of SYS6006
2 trials
phase_1
cspc-zhongqi-pharmaceutical-technology-co-ltd
SIM0916
1 trial
phase_3
simcere-pharmaceutical-co-ltd
Deuremidevir Hydrobromide for Suspension
1 trial
phase_2
vigonvita-life-sciences
High-dose of LVRNA009
1 trial
phase_1
aim-vaccine-co-ltd
Middle-dose of LVRNA009
1 trial
phase_1
aim-vaccine-co-ltd
Omicron COVID-19 Vaccine (Vero Cell), Inactivated
1 trial
phase_1_2
china-national-biotec-group-company-limited
Low-dose of LVRNA009
1 trial
phase_1
aim-vaccine-co-ltd
8 unique interventions2 categories

Analytics

Trial Phases

Phase 14
Phase 22
Phase 31

Trial Status

Completed1
Recruiting1
Other4

Role Distribution

Principal Investigator6
PI Rate100%

Activity Timeline

Clinical Trials (6)

NCT07402512Phase 3Recruiting
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
Respiratory Syncytial Virus Infection
PrincipalinvestigatorStart date: 2026-03-11
NCT06206720Phase 2Completed
A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
Respiratory Syncytial Virus Infection
PrincipalinvestigatorStart date: 2024-01-31
NCT05354063Phase 1Unknown
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.
SARS-CoV-2
PrincipalinvestigatorStart date: 2022-06-01
NCT05365724Phase 1/2Unknown
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above
COVID-19
PrincipalinvestigatorStart date: 2022-05-01
NCT05354089Phase 1Unknown
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
SARS-CoV-2
PrincipalinvestigatorStart date: 2022-04-27
NCT05364047Phase 1Unknown
Clinical Trial of SARS-CoV-2 mRNA Vaccine in China
COVID-19
PrincipalinvestigatorStart date: 2021-07-31

Research Network

Collaboration Network

7 collaborators·10 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Therapeutic Areas

COVID-192Respiratory Syncytial Virus Infections2SARS-CoV-22

Affiliations

Shulan (Hangzhou) Hospital

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Guiling Chen

Shulan (Hangzhou) Hospital

Moderately Similar
3 trials

Shared therapeutic areas:

SARS-CoV-2COVID-19

Worked with same sponsors:

AIM Vaccine Co., Ltd.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.+2 more
Collaborated on 3 trials
Similarity Score32%

Sabine Hazan, MD

ProgenaBiome

Related
41 trials

Shared therapeutic areas:

COVID-19SARS-CoV-2
Similarity Score20%

Matthew J Memoli, M.D.

National Institute of Allergy and Infectious Diseases (NIAID)

Related
15 trials

Shared therapeutic areas:

SARS-CoV-2COVID-19
Similarity Score20%

Helen Heslop, MD

Baylor College of Medicine

Related
17 trials

Shared therapeutic areas:

COVID-19SARS-CoV-2
Similarity Score20%

Yuwen Su

Sir Run Run Hosipital Nanjing Medical University

Related
2 trials

Shared therapeutic areas:

SARS-CoV-2

Worked with same sponsors:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Collaborated on 2 trials
Similarity Score18%

Fengli Zhao

Yuncheng Central Hospital

Related
1 trials

Shared therapeutic areas:

COVID-19

Worked with same sponsors:

AIM Vaccine Co., Ltd.Shulan (Hangzhou) Hospital+1 more
Collaborated on 1 trial
Similarity Score14%

Jinlian Bi

Xiangya Boai Rehabilitation Hospital

Related
1 trials

Shared therapeutic areas:

COVID-19

Worked with same sponsors:

AIM Vaccine Co., Ltd.Shulan (Hangzhou) Hospital+1 more
Collaborated on 1 trial
Similarity Score14%

hanmin liu

West China Second University Hospital

Related
1 trials

Shared therapeutic areas:

Respiratory Syncytial Virus Infections

Worked with same sponsors:

Simcere Pharmaceutical Co., Ltd
Collaborated on 1 trial
Similarity Score14%

Zhen Qin

Shulan (Hangzhou) Hospital

Related
1 trials

Shared therapeutic areas:

Respiratory Syncytial Virus Infections

Worked with same sponsors:

Vigonvita Life Sciences
Collaborated on 1 trial
Similarity Score14%

Xiaolong Qi, MD

LanZhou University

Related
8 trials

Shared therapeutic areas:

COVID-19

Worked with same sponsors:

Shulan (Hangzhou) Hospital
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT07402512Phase 3PrincipalInvestigator

A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children

Respiratory Syncytial Virus Infection
Recruiting
NCT06206720Phase 2PrincipalInvestigator

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

Respiratory Syncytial Virus Infection
Completed
NCT05354063Phase 1PrincipalInvestigator

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.

SARS-CoV-2
Unknown
NCT05365724Phase 1/2PrincipalInvestigator

A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above

COVID-19
Unknown
NCT05354089Phase 1PrincipalInvestigator

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.

SARS-CoV-2
Unknown
NCT05364047Phase 1PrincipalInvestigator

Clinical Trial of SARS-CoV-2 mRNA Vaccine in China

COVID-19
Unknown

All 6 trials loaded